Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Key Takeaways

• Pulse Biosciences presenting at Needham Virtual Healthcare Conference
• Presentation scheduled April 16, 2026, 9:30 am ET
• Focus on nPulse nanosecond pulsed field ablation platform
• Targeting atrial fibrillation and soft‑tissue ablation markets
• Live webcast accessible via investor website

Summary

Pulse Biosciences (Nasdaq: PLSE) will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 9:30 am ET. The company will showcase its proprietary nPulse™ platform, which uses nanosecond pulsed field ablation (nsPFA™) to treat atrial fibrillation and perform soft‑tissue ablation. A live and recorded webcast will be available on the investor website. The appearance aims to raise visibility among healthcare investors and highlight progress toward commercializing the technology.

Pulse Analysis

The Needham Virtual Healthcare Conference has become a pivotal stage for emerging med‑tech firms to court institutional investors. By securing a slot, Pulse Biosciences gains exposure to a focused audience of healthcare analysts and capital allocators, potentially accelerating its fundraising timeline. The conference’s virtual format also broadens reach, allowing analysts worldwide to evaluate the company’s pipeline without geographic constraints.

Pulse’s nPulse™ platform leverages nanosecond pulsed field ablation, delivering ultra‑short electrical bursts that disrupt cellular membranes while sparing surrounding extracellular matrix. This non‑thermal approach promises faster lesion creation, reduced collateral damage, and shorter procedure times compared with conventional radiofrequency or cryo‑ablation. Early pre‑clinical data suggest efficacy in isolating pulmonary veins for atrial fibrillation and in precise soft‑tissue removal, positioning nPulse as a versatile tool across cardiology and surgical specialties.

The market opportunity is substantial: atrial fibrillation affects over 6 million Americans, driving a $6 billion annual treatment spend. If nPulse can demonstrate superior safety and outcomes, it could capture a meaningful share of this fragmented space while also opening revenue streams in orthopedic and oncologic ablation. Competitive pressures from established ablation vendors mean Pulse must advance clinical trials and secure regulatory clearance swiftly. Successful conference exposure may translate into strategic partnerships or licensing deals, accelerating time‑to‑market and delivering value to both patients and shareholders.